Advice on the testing, treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patients medical history
a , Representative images of intestinal NE morphology in wild-type, daf-16(mu86), hif-1(ok2564) or skn-1(zu169) animals grown on cco-1 RNAi bacteria
GIP Agonism Reduces appetite, nausea, and bone resorption Increases insulin & glucagon production, and lipogenesis Glucagon Agonism Reduces appetite, food intake, and gastric emptying Increases insulin production, energy expenditure, and nausea Amylin Agonism Reduces appetite, food intake, glucagon production, and gastric emptying Increases energy expenditure Reduces bone resorption and increases bone production PYY Agonism Reduces appetite, food intake, and gastric emptying Increases energy expenditure and nausea The Cost Challenge for Payers The cost of GLP-1s continues to be a significant concern for payers between skyrocketing costs and utilization over the past several years
Sleep and Glutathione This is Sleep Awareness Week, the perfect time to dive deep into the power of sleep
Denmarks Novo Nordisk had already won the race to get an oral GLP-1 drug onto the market (with a version of Wegovy in December): but Eli Lillys drug could shake up the market
Gastric Protection Models From Sikiric et al
